RXi Pharmaceuticals (NASDAQ: [[ticker:RXII]]), the Worcester, MA-based developer of RNA interference drugs, said today that Noah Beerman has replaced Tod Woolf as president and CEO. Beerman, 47, was most recently chief business officer of Indevus Pharmaceuticals. The company said the leadership switch was part of a succession plan as it looks to advance into product development. Woolf will remain on the company’s scientific advisory board.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
